@article{996ba52895cf4369ab801494debf6b38,
title = "A venetoclax bench-to-bedside story",
author = "DiNardo, {Courtney D.} and Konopleva, {Marina Y.}",
note = "Funding Information: C.D.D. reports research funding from Abbvie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc and Loxo; advisory/ consulting for Abbvie, Agios, Celgene/BMS, Daiichi Sankyo, ImmuneOnc, Novartis and Takeda; and stock options from Notable Labs. M.Y.K. reports research funding from AbbVie, Genentech, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Sanofi, Rafael and Forty-Seven; advisory/consulting for AbbVie, Genentech, F. Hoffmann–La Roche, Cellectis, Stemline Therapeutics, Kisoji and Forty-Seven; and stock options/royalties from Reata Pharmaceuticals. Funding Information: C.D.D. and M.Y.K. are funded by US National Institutes of Health/National Cancer Institute grant R01CA235622 (principal investigator, M.Y.K.; 17 June 2019 to 31 May 2024). This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672 and the MD Anderson Cancer Center Leukemia SPORE CA100632.",
year = "2021",
month = jan,
doi = "10.1038/s43018-020-00165-6",
language = "English (US)",
volume = "2",
pages = "3--5",
journal = "Nature Cancer",
issn = "2662-1347",
publisher = "Nature Research",
number = "1",
}